Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 29;10(3):370–379. doi: 10.1080/19420862.2018.1424610

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — Molecular size and FcγR activation property of the rituximab/ADA immune complex, (A) DLS analysis of the rituximab/ADA immune complex. The size distribution of rituximab (blue), ADA (green) and the rituximab/ADA complex at a molar ratio of 1:1 (red) is shown. (B) FcγRIIa activation by ADAs in the presence or absence of rituximab was measured by using Jurkat/FcγRIIa/NFAT-Luc reporter cells. Infliximab was used as a negative control. Data represent the mean + SEM (n = 3). (C) Correlation between the FcγRIIa activation and the size of the immune complex. The FcγRIIa activation (in relative light units: RLU) is plotted against the size of the immune complex (diameter). The dashed line is a regression line (R square is 0.848).